INTRODUCTION {#s1}
============

Doublecortin-like kinase 1 (DCLK1) is a microtubule associated kinase, containing two doublecortin domains in the N-terminus for regulation of microtubule polymerization and a serine/threonine protein kinase domain in the C-terminus. It also shows substantial homology to Ca2+/calmodulin-dependent protein kinase. In between the N and C termini, there is a serine/proline-rich domain for mediating multiple protein-protein interactions \[[@R1]\]. Its function was first described in neuronal migration and development \[[@R2]\]. Recently, its expression has been found in colon cancers \[[@R3]-[@R5]\], pancreatic \[[@R6]\] and esophageal cancers \[[@R7]\].

DCLK1 has been proposed as a cancer stem cell marker for gastrointestinal cancers. DCLK1 specifically marked cancer stem cells (CSC) that self-renew and generate tumor progeny in *Apc^Min/+^* mice \[[@R8]\]. DCLK1 positive differentiated tuft cells can be activated by tissue injury and initiate colon cancer \[[@R9]\]. In pancreatic cancers, DCLK1 positive cells displayed increased sphere forming and tumor initiating capacity \[[@R10]\], and enhanced epithelial-mesenchymal transition (EMT), a process closely linked to the acquisition of stem cell properties, via regulation of microRNA biogenesis \[[@R4], [@R6], [@R11]\]. Interestingly, colorectal cancer with high DCLK1 expression had increased cancer specific mortality \[[@R5]\]. Upregulation of DCLK1 expression in blood circulation was found in chemoradiotherapy-treated colorectal cancer patients \[[@R12]\].

Aberrant DCLK1 expression was detected in IBC \[[@R13]\]. Knockdown of oncogenic miR-21 in IBC was accompanied by a decrease in DCLK1 expression \[[@R14]\]. Apart from these, no other information is currently available. It is not clear whether the aberrant DCLK1 expression contributed to IBC tumor aggressiveness as in gastrointestinal cancers. In addition, CSC heterogeneity exists in different breast cancer subtypes \[[@R15]\], and the commonly used CSC markers did not identify all CSC populations. It will be interesting to explore using DCLK1 as a CSC marker in breast cancer subtypes.

In this study, we evaluated the expression of DCLK1 in a large cohort of breast cancer by immunohistochemistry (IHC), its association with clinico-pathological features and other biomarkers (including CSC markers) expression, as well as the relationship with breast cancer outcome.

RESULTS {#s2}
=======

A total of 1132 cases were included in this cohort. The mean patients\' age was 54.6±12.7 (range 22-97) years. The mean tumor size was 2.67±1.52 (range 0.2-13.9) cm. One hundred and seventy three cases (15.3%) were grade I, 457 cases (40.4%) were grade II and 502 cases (44.3%) were grade III. Nine hundred and eighty seven cases were IBC of no special type (IBC-NST). There were 35 cases of invasive lobular cancers (ILC), 48 cases of breast cancers with medullary features, nine cases of mucinous cancers and eight cases of neuroendocrine cancers. The remaining 45 cases were of other miscellaneous histologic types, including micropapillary carcinoma, papillary carcinoma, tubular carcinomas, tubulo-lobular carcinoma and metaplastic carcinomas. Details of the clinico-pathologic features are summarized in Table [2](#T2){ref-type="table"}. Overall, 418 cases (36.9%) were DCLK1 high and 513 cases (63.1%) were DCLK1 low. Representative staining is shown in Figure [1](#F1){ref-type="fig"}.

###### Antibodies used for IHC analysis

  Markers               Company               Clone        Dilution      Antigen retrival   Incubation condition (min, °C)   Assessment   cutoff
  --------------------- --------------------- ------------ ------------- ------------------ -------------------------------- ------------ -------------
  ER                    Neomarkers            SP1          Pre-diluted   EDTA pH8           32,37                            N            1%
  PR                    Ventana               IE2          Pre-diluted   EDTA pH8           32,37                            N            1%
  AR                    Dako                  AR441        1:100         EDTA pH8           56,37                            N            1%
  Ki67                  Ventana               41912        Pre-diluted   EDTA pH8           32,37                            N            14%
  EGFR                  Ventana               3C6          Pre-diluted   EDTA pH8           32,37                            M            5%
  HER2                  Ventana               4B5          Pre-diluted   EDTA pH8           16,37                            M            3+
  CK5/6                 Dako                  D5/16 B4     1:40          EDTA pH8           32,37                            C,M          5%
  CK14                  Neomarkers            LL002        1:100         EDTA pH8           32,37                            C,M          5%
  c-kit                 Dako                  104D2        1:300         EDTA pH8           32,37                            C,M          5%
  P63                   Ventana               4A4          Pre-diluted   EDTA pH8           32,37                            N            5%
  Synaptophysin (SYN)   Novocastra            27G12        1:50          EDTA pH8           32,37                            C,M          1%
  Chromogranin (CG)     Biogene               MU-126-UC    1:200         EDTA pH8           32,37                            C,M          1%
  SOX2                  Ventana               SP76         Pre-diluted   EDTA pH8           32,37                            N            1%
  vimentin              Dako                  V9           1:2000        EDTA pH8           24, RT                           C, M         10%
  p-cadherin            BD transduction lab   56/p-cad     1:200         EDTA pH8           32,37                            C,M          10%
  CD44                  Ventana               SP37         Pre-diluted   EDTA pH8           32, 37                           M            5%
  ALDH                  BD transduction lab   44/ALDH      1:600         EDTA pH8           32, 37                           C            5%
  DCLK1                 Abcam                 Polyclonal   1:100         Citrate pH6        32, 37                           C            IHC score 4

'N': nuclear; 'C': cytoplasmic; 'M': membraneous

###### Correlation of DCLK1 expression with clinic-pathological features

                          DCLK1                                  IHC score             
  ------------ ---------- ---------- ---------- ------ --------- ----------- --------- ---------
  Grade        1          94         79         173    \<0.001   3.3 (2.7)   3 (0-6)   \<0.001
               2          259        198        457              3.0 (2.6)   3 (0-5)   
               3          361        141        502              2.3 (2.2)   2 (0-4)   
               Total      714        418        1132                                   
  FF           Absence    519        323        842    0.045     2.8 (2.5)   2 (0-5)   0.208
               Presence   184        85         269              2.6 (2.4)   2 (0-4)   
               Total      703        408        1111                                   
  necrosis     Absence    538        342        880    0.005     2.9 (2.5)   2 (0-5)   \<0.001
               Presence   151        60         211              2.7 (2.5)   2 (0-4)   
               Total      689        402        1091                                   
  EIC          Absence    565        325        890    0.680     2.8 (2.5)   2 (0-5)   0.741
               Presence   142        87         229              2.7 (2.5)   2 (0-4)   
               Total      707        412        1119                                   
  LVI          Absence    472        309        781    0.004     2.8 (2.5)   3 (0-5)   0.034
               Presence   207        89         296              2.5 (2.2)   2 (0-4)   
               Total      679        398        1077                                   
  pN           0          335        222        557    0.002     2.9 (2.5)   3 (0-5)   0.028
               1          220        120        340              2.6 (2.4)   2 (0-4)   
               2          84         39         123              2.5 (2.3)   2 (0-4)   
               3          60         19         79               2.1 (2.2)   2 (0-3)   
               Total      699        400        1099                                   
  pT           1          280        182        462    0.078     2.9 (2.6)   3 (0-5)   0.442
               2          370        203        573              2.6 (2.4)   2 (0-4)   
               3          41         19         60               2.5 (2.3)   2 (0-4)   
               4          13         5          18               2.0 (2.0)   2 (0-3)   
               Total      704        409        1113                                   
  Molecular    Lum A      283        253        536    \<0.001   3.3 (2.6)   3 (0-6)   \<0.001
               Lum B      210        110        320              2.7 (2.3)   2 (0-4)   
               HER2-OE    87         25         112              2.1 (1.9)   2 (0-3)   
               BLBC       52         16         68               2.0 (2.1)   2 (0-4)   
               5NP        75         10         85               1.2 (1.7)   0 (0-2)   
               Total      707        414        1121                                   
  Age          Mean       54.1       55.5       54.6   0.266     \-          \-        \-
               SD         12.2       13.5       12.7                                   
               Range      22-94      27-97                                             
  Tumor size   Mean       2.71       2.60       2.67   0.076     \-          \-        \-
               SD         1.48       1.57       1.51                                   
               Range      0.3-11.0   0.2-13.9                                          

"SD": standard deviation; "IQR": Interquartile range

![Representative immunohistochemical staining of DCLK1 (x400)\
High cytoplasmic immunoreactivity of DCLK1 in tumor cells but not in surrounding stroma. All micrographs were taken with a 40x objective, Nikon microscope equipped with a digital color camera and software.](oncotarget-07-1464-g001){#F1}

Correlation with clinico-pathologic features, biomarkers and molecular subtypes {#s2_1}
-------------------------------------------------------------------------------

High DCLK1 expression correlated with lower grade (*p* \< 0.001), the absence of FF (*p* =0.045), the absence of necrosis (*p* = 0.005), the absence of LVI (*p* = 0.004) and lower pN stage (*p* = 0.002) but not age, EIC and pT stage (Table [2](#T2){ref-type="table"}).

Among the 1121 invasive cancers with complete IHC data for molecular subtypes classification, 536 (47.8%) were luminal A, 320 (28.5%) were luminal B, 112 (10.0%) were HER2-OE and 153 (13.7%) were triple negative breast cancers (TNBC) (including 68 (6.1%) BLBC and 85 (7.6%) unclassified). The DCLK1 expression rate was 47.2% in luminal A, 34.4% in luminal B, 22.3% in HER2-OE and 17.0% in TNBC (23.5% in BLBC and 11.8% in unclassified). DCLK1 expression showed a differential expression in different molecular subtypes with the highest prevalence in luminal cancers (*p* \< 0.001) (Table [2](#T2){ref-type="table"}).

In line with that, DCLK1 also correlated positively with the expression of ER and PR (*p* \< 0.001 for both). Additionally, DCLK1 correlated with expression of AR (*p* = 0.010), SYN (*p* \< 0.001) and CG (\<0.001) positively but negatively with HER2 (*p* = 0.001), Ki67 (*p* \< 0.001), c-Kit (*p* = 0.034), CK5/6 (*p* = 0.030) and p-cadherin (*p* \< 0.001). There was no significant correlation with EGFR, p63, CK14, CD44, ALDH1, vimentin and SOX2 (Table [3](#T3){ref-type="table"}). By multivariate analysis, only LVI (OR=0.590, *p* = 0.001, 95% CI=0.427-0.817), ER (OR=2.316, *p* \< 0.001, 95% CI=1.648-3.255), CG (OR=1.611, *p* = 0.019,95% CI=1.080-2.401) and SYN (OR=1.655, *p* \< 0.001,95% CI=1.298-2.110) were found to be independent parameters associated with DCLK1 expression ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Similar results were obtained when DCLK1 expression was analyzed as a continuous variable, except for FF (Tables [2](#T2){ref-type="table"}-[3](#T3){ref-type="table"} and [Supplementary Table S2](#SD1){ref-type="supplementary-material"}).

###### Association of DCKL1 expression with biomarkers

                        DCKL1                          IHC score                
  ------------- ------- ------- ----- ------ --------- ----------- ------------ ---------
  ER            Neg     263     65    328    \<0.001   1.9 (2.0)   2 (0-3)      \<0.001
                Pos     449     350   799              3.1 (2.5)   3 (0-5)      
                Total   712     415   1127                                      
  PR            Neg     286     93    379    \<0.001   2.1 (2.4)   2 (0-3)      \<0.001
                Pos     420     322   742              3.1 (2.5)   3 (2-5)      
                Total   706     415   1121                                      
  AR            Neg     444     235   679    0.043     2.5 (2.4)   2 (0-5)      0.004
                Pos     270     184   454              3.0 (2.4)   3 (0-5)      
                Total   714     419   1133                                      
  EGFR          Neg     664     394   1058   0.297     2.8 (2.5)   2 (0-5)      0.793
                Pos     41      18    59               2.6 (2.2)   2 (0-5)      
                Total   705     412   1117                                      
  HER2          Neg     552     358   910    0.001     2.9 (2.5)   3 (0-5)      0.002
                Pos     158     59    217              2.2 (2.0)   2 (0-4)      
                Total   710     417   1127                                      
  Ki67          low     402     289   691    \<0.001   3.0 (2.5)   3 (0-6)      \<0.001
                high    302     126   428              2.4 (2.3)   2 (0-4)      
                Total   704     415   1119                                      
  c-KIT         Neg     578     359   937    0.034     2.8 (2.5)   2 (0-5)      0.157
                Pos     124     53    177              2.5 (2.2)   2 (0-4)      
                Total   702     412   1114                                      
  P63           Neg     674     399   1073   0.470     2.8 (2.5)   2 (0-5)      0.888
                Pos     30      14    44               2.6 (2.1)   2 (2-5)      
                Total   704     413   1117                                      
  CK5/6         Neg     617     381   998    0.030     2.8 (2.5)   3 (0-5)      0.022
                Pos     85      33    118              2.2 (2.1)   2 (0-4)      
                Total   702     414   1116                                      
  CK14          Neg     658     390   1048   0.465     2.8 (2.5)   2 (0-5)      0.313
                Pos     47      23    70               2.4 (2.1)   2 (0-4)      
                Total   705     413   1118                                      
  SYN           Neg     659     329   988    \<0.001   2.5 (2.4)   2 (0-4)      \<0.001
                Pos     44      85    129              4.5 (2.4)   5 (4-7)      
                Total   703     414   1117                                      
  CG            Neg     690     377   1067   \<0.001   2.7 (2.4)   2 (0-5)      \<0.001
                Pos     11      39    50               5.2 (2.3)   6 (4-7)      
                Total   701     416   1117                                      
  SYN/ and CG   Neg     650     325   975    \<0.001   2.5 (2.4)   2 (0-4)      \<0.001
                Pos     47      88    135              4.5 (2.4)   5 (3-7)      
                Total   697     413   1110                                      
  p-Cadherin    Neg     503     343   846    \<0.001   3.0 (2.5)   3 (0-5)      \<0.001
                Pos     192     64    256              2.1 (2.1)   2 (0-4)      
                Total   695     407   1102                                      
  Vimentin      Neg     604     354   958    0.928     2.8 (2.5)   3 (0-5)      0.670
                Pos     94      56    150              2.7 (2.4)   2.5 (0-4)    
                Total   698     410   1108                                      
  CD44          Neg     217     135   352    0.895     2.8 (2.5)   3 (0-5)      0.180
                Pos     105     67    172              3.1 (2.4)   3 (1-5)      
                Total   322     202   524                                       
  ALDH          Neg     305     187   492    0.569     2.9 (2.5)   3 (0-5)      0.725
                Pos     20      15    35               3.1 (2.6)   2 (2-5)      
                Total   325     202   527                                       
  SOX2          Neg     260     162   422    0.901     2.9 (2.5)   3 (0-5)      0.903
                Pos     64      41    105              2.9 (2.3)   3 (0-4.75)   
                Total   324     203   527                                       

"SD": standard deviation; "IQR": Interquartile range

Relationship with clinico-pathologic features and biomarkers in IBC-NED {#s2_2}
-----------------------------------------------------------------------

IBC-NED was defined by ≥ 1% expression of GC and/or SYN or showing morphological NED features \[[@R16]-[@R18]\]. All cases with morphologic NED features in fact showed NED marker expression. According to this criteria, 135 cases (12.1%) were classified as IBC-NED. Focal expression (1-49%) of either neuroendocrine markers was found in 81 cases and diffuse (≥50%) expression in 54 cases. Of these 135 cases, there were 112 IBC-NST. Others included 2 ILC, 4 carcinomas with medullary features, 3 mucinous carcinomas, 8 morphologic neuroendocrine carcinomas, 3 papillary carcinomas, 2 metaplastic carcinomas and one invasive micropapillary carcinoma. By molecular classification, 74 were luminal A, 54 were luminal B, 3 were HER2-OE and 3 were unclassified. IBC-NED (1% cutoff) were associated with the absence of necrosis (*p* = 0.028), the presence of LVI (*p* = 0.005), older age (*p* \< 0.001) and luminal cancers (*p* \< 0.001). Regarding biomarkers, it also correlated positively with ER and PR (*p* \< 0.001 for both) and negatively with HER2 (*p* = 0.003), EGFR (*p* = 0.033), basal and EMT markers (including p63, c-kit, CK5/6, CK14, p-cadherin and vimentin; *p* ≤ 0.034) ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}). Concentrating on IBC- NED with diffuse NED marker expression (50% cutoff), there were significant associations with necrosis, older age, ER, PR, HER2, c-kit, CK5/6 and p-cadherin, and these associations were similar to all IBC-NED (1% cutoff) (*p* ≤ 0.034). For LVI, EGFR and vimentin ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}), the associations with all IBC-NED were not seen with IBC-NED (diffuse).

In IBC-NED, DCLK1 expression remained associated with lower grade (*p* \< 0.001), lower pN stage (*p* ≤ 0.012), lower pT stage (*p* ≤ 0.042), PR positivity (*p* ≤ 0.019), HER2 negativity (*p* = 0.002), low Ki67 (*p* ≤ 0.004) and diffuse NED expression (*p* \< 0.001) regardless categorical or continuous variables analyses (Table [4](#T4){ref-type="table"}).

###### Association of DCLK1 with clinico-pathological features and biomarkers in IBC-NED

                          DCLK1                                IHC score                   
  ------------ ---------- --------- --------- ------ --------- ----------- --------------- ---------
  Grade        1          2         14        16     \<0.001   5.8 (1.8)   7 (4.5-7)       \<0.001
               2          17        52        69               4.9 (2.2)   6 (3.5-7)       
               3          28        22        50               3.3 (2.4)   3 (1.5-6)       
               Total      47        88        135                                          
  FF           Absence    34        75        109    0.079     4.6 (2.4)   5 (2.5-7)       0.366
               Presence   12        12        24               4.1 (2.4)   3.5 (2.5-6.5)   
               Total      46        87        133                                          
  necrosis     Absence    39        76        115    0.440     4.5 (2.4)   5 (3-7)         0.463
               Presence   7         9         16               3.9 (2.9)   4 (0.5-7)       
               Total      46        85        131                                          
  EIC          Absence    39        71        110    0.645     4.4 (2.5)   5               0.841
               Presence   7         16        23               4.7 (2.1)   5               
               Total      46        87        133                                          
  LVI          Absence    20        59        79     0.006     4.8 (2.3)   5 (3-7)         0.093
               Presence   24        25        49               4.0 (2.5)   4 (2-7)         
               Total      44        84        128                                          
  pN           0          16        47        63     0.001     4.9 (2.4)   6 (3-7)         0.012
               1          15        25        40               4.2 (2.3)   4 (2-6)         
               2          6         7         13               4.0 (2.5)   4 (2-6.5)       
               3          10        4         14               2.9 (2.1)   3 (1.5-4)       
               Total      47        83        130                                          
  pT           1          14        39        53     0.028     5.0 (2.3)   6 (3-7)         0.042
               2          29        42        71               4.0 (2.5)   4 (2-6)         
               3          1         2         3                5.3 (2.1)   6 (4.5-6.5)     
               4          3         1         4                2.8 (2.5)   2.5 (1-4.5)     
               Total      47        84        131                                          
  Molecular    Lum A      14        60        74     \<0.001   5.2 (2.1)   6 (4-7)         \<0.001
               Lum B      28        26        54               3.5 (2.4)   3 (2-6)         
               HER2-OE    3         0         3                1.7 (1.5)   2 (0-3)         
               BLBC       0         0         0                \-          \-              
               5NP        2         1         3                3.0 (3.0)   3 (0-3)         
               Total      47        87        134                                          
  Age          Mean       56.6      59.7      58.7   0.249     \-          \-              \-
               SD         13.0      14.0      13.7             \-          \-              
               Range      30-80     31-83                                                  
  Tumor size   Mean       2.86      2.58      2.68   0.208     \-          \-              \-
               SD         1.35      1.27      1.31             \-          \-              
               Range      1.0-7.0   0.8-8.0                                                
  Biomarkers                                                                               
  ER           Neg        6         3         9      0.065     2.8 (2.5)   3 (0-5.5)       0.031
               Pos        41        85        126              4.6 (2.3)   5 (3-7)         
               Total      47        88        135                                          
  PR           Neg        14        11        25     0.020     3.6 (2.2)   3 (2-5.5)       0.019
               Pos        33        77        110              4.7 (2.4)   5 (3-7)         
               Total      47        88        135                                          
  AR           Neg        28        52        80     0.957     5.2 (2.1)   5 (3-7)         0.458
               Pos        19        36        55               4.7 (2.4)   5 (2-7)         
               Total      47        88        135                                          
  EGFR         Neg        47        86        133    0.543     4.4 (2.4)   5 (3-7)         0.534
               Pos        0         2         2                5.5 (2.2)   5.5 (4-7)       
               Total      47        88        135                                          
  HER2         Neg        37        84        121    0.002     4.6 (2.3)   6 (3-7)         0.002
               Pos        10        3         13               3.7 (2.4)   3 (0-4)         
               Total      47        87        134                                          
  Ki67         low        21        63        84     0.002     4.9 (2.3)   6 (3.5-7)       0.004
               high       26        25        51               3.7 (2.4)   3 (2-6)         
               Total      47        88        135                                          
  c-KIT        Neg        41        83        124    0.152     4.5 (2.5)   5 (2-7)         0.501
               Pos        6         5         11               4.2 (1.8)   3 (3-6)         
               Total      47        88        135                                          
  P63          Neg        45        88        133    0.343     4.5 (2.4)   5 (3-7)         0.263
               Pos        1         0         1                2           2               
               Total      46        88        134                                          
  CK5/6        Neg        46        86        132    0.546     4.4 (2.4)   5 (3-7)         0.238
               Pos        0         2         2                6.5 (0.7)   6.5 (6-7)       
               Total      48        88        134                                          
  CK14         Neg        46        87        133    1.0       4.5 (2.4)   5 (3-7)         0.933
               Pos        1         1         2                4.5 (3.5)   4.5 (2-4.5)     
               Total      47        88        135                                          
  CG/SYN       \<50%      37        40        77     \<0.001   3.7 (2.4)   4 (2-7)         \<0.001
               ≥50%       10        48        58               5.5 (2.1)   7 (5-7)         
               Total      47        88        135                                          
  p-Cadherin   Neg        39        79        118    0.182     4.5 (2.4)   5 (3-7)         0.158
               Pos        8         8         16               3.8 (2.4)   3.5 (2-6)       
               Total      47        87        134                                          
  Vimentin     Neg        46        81        127    0.421     4.4 (2.4)   5 (2-7)         0.359
               Pos        1         6         7                5.4 (1.5)   6 (4-7)         
               Total      47        87        134                                          
  CD44         Neg        8         24        32     1.0       5.3 (2.2)   6 (3.5-7)       0.376
               Pos        5         13        21               4.7 (2.3)   5 (3.5-7)       
               Total      13        40        53                                           
  ALDH1        Neg        12        38        50     1.0       5.0 (2.2)   6 4-7)          0.573
               Pos        1         2         3                5.7 (2.3)   7 (3-7)         
               Total      13        40        53                                           
  SOX2         Neg        8         32        40     0.179     5.2 (2.2)   6 (4-7)         0.261
               Pos        5         8         13               4.5 (2.3)   4 (3-7)         
               Total      13        40        53                                           

"SD": standard deviation; "IQR": Interquartile range

Relationship with outcome {#s2_3}
-------------------------

Follow up data were available for 987 cases with a mean follow-up duration of 65.6 months (range 1--210 months). One hundred and forty nine cases (15.1%) had breast cancer mortality or relapse. Among them, 116 cases (11.8%) had breast cancer specific mortality. DCLK1 expression was associated with significantly better OS (log-rank=5.753, *p* = 0.016) and DFS (log-rank=12.104, *p* = 0.001). When segregating the cases into luminal and non-luminal cancers, DCLK1 expression was associated with better DFS significantly in luminal cancers (log-rank=5.883, *p* = 0.015) but not in non-luminal cancers (log-rank=0.389, *p* = 0.533).

It appears that the association of DCLK1 with outcome in luminal cancers is mainly related to the relationship with IBC-NED, which are clustered within the luminal group of cancers. Analysis of the prognostic impact of DCLK1 in the IBC-NED cases and non-NED luminal cases found that DCLK1 expression was associated with better DFS (log-rank= 12.187, *p* \< 0.001) and OS (log-rank=7.222, *p* = 0.007) in IBC-NED but not in non-NED luminal cancers (Figure [2](#F2){ref-type="fig"}). Recent investigations suggested adverse prognosis of IBC-NED \[[@R16], [@R19]\]. This study also showed worse OS (log-rank=4.658, *p* = 0.031) and DFS (log-rank=9.294, *p* = 0.002) in IBC-NED than luminal cancers without NED. The prognostic impact on DFS of IBC-NED was independent of ER, PR, HER2, Ki67, grade, age, tumor size and nodal involvement (HR=1.756, *p* = 0.041 with reference to non-NED luminal). Interestingly, those IBD-NED with worse outcome showed focal but not diffuse NED expression ([supplementary figure 1S](#SD1){ref-type="supplementary-material"}). As DCLK1 was associated with diffuse NED expression, we then compared the patients\' parameters and outcome based on groupings stratified by different levels of neuroendocrine and DCLK1 expression. IBC-NED with low DCLK1 expression showed the lowest DFS rate, when compared to non-NED luminal cancers regardless of the neuroendocrine expression pattern (DCLK1 low/ neuroendocrine focal: log-rank=8.861, *p* = 0.003; DCLK1 low/ neuroendocrine diffuse: log-rank=7.211, *p* = 0.007) (Figure [3](#F3){ref-type="fig"}). Of note, DCLK1 was found also to have independent favorable prognostic impact on DFS of IBC-NED (HR=0.288, *p* = 0.011, 95%CI= 0.111-0.748) after adjustment of grade, age, tumor size, LVI, pN stage, HER2, Ki67, PR and neuroendocrine markers expression ([Supplementary Table S4](#SD1){ref-type="supplementary-material"}).

![Kaplan-meier analysis of DFS and OS on non-NED luminal and IBC-NED cancers according to DCKL1 expression\
DFS in non-NED luminal cancers **A**. and IBC-NED **B**. with different level of DCLK1 expression was compared. OS in non-NED luminal cancers **C**. and IBC-NED **D**. with different level of DCLK1 expression was compared. DCKL1 expression was related to DFS and OS in IBC-NED but not non-NED luminal cancers.](oncotarget-07-1464-g002){#F2}

![Kaplan-meier analysis on DFS of non-NED luminal and IBC-NED according to NED marker and DCKL1 expression\
DCKL1 low IBC-NED regardless of focal or diffused NED marker expression showed worse DFS compared to non-NED luminal cancers.](oncotarget-07-1464-g003){#F3}

DISCUSSION {#s3}
==========

In this study, the expression of DCLK1 in a large cohort of breast cancer was analyzed. In contrast to its cancer initiating roles in gastrointestinal tumors, DCLK1 expression in breast cancer did not appear to be related to stem cell features and aggressive behavior. No positive correlation was observed with other breast CSC markers. Nonetheless, DCLK1 was negatively correlated with grade, basal (c-kit and CK5/6) as well as EMT (p-cadherin) markers. DCLK1 was more frequently found in luminal cancers than basal-like and HER2-OE subtypes \[[@R15], [@R20], [@R21]\], associated with IBC-NED and potentially an independent favorable prognostic factor in these cancers.

The diagnosis of IBC-NED has been controversial. It was first defined by the presence of morphologic features similar to those of neuroendocrine tumors of the gastrointestinal tract or of the lung. However, classic neuroendocrine morphology is comparatively rare in breast cancer, thus its significance has been debatable for some time. Recently, a formal categorization of this tumor in WHO classification has been established. Apart from the morphologic features (including well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinoma or small cell carcinoma), it has been defined with the expression of NED markers in over 50% of the tumor cell population in the 2003 WHO classification \[[@R22]\]. In the latest 2012 classification \[[@R18]\], it was revised to include all tumors expressing NED markers to a greater or lesser degree. The prognostic significance of NED per se in IBC-NED has also been uncertain, with reports suggested no effects on prognosis \[[@R23]-[@R25]\], better \[[@R26], [@R27]\] or worse \[[@R16], [@R19]\] prognosis. In the current study, the latest WHO criteria were adopted for diagnosis of IBC-NED \[[@R18]\]. In agreement with the others \[[@R16], [@R19], [@R28], [@R29]\], IBC-NED was mainly associated with luminal cancers. However, IBC-NED was not associated with low tumor grade or favorable outcome as would be expected for luminal cancers. This result corroborated with heterogeneity in IBC-NED, which encompass both low grade special subtypes and aggressive high grade cancers \[[@R17]\]. In contrast to the previous reports showing the poor prognosis of diffuse neuroendocrine markers expression \[[@R19]\], this study showed poorer outcome in patients with focal rather than diffuse NED expression in IBC-NED. One study applied similar criteria demonstrated similar poor outcomes in IBC with diffuse and focal neuroendocrine marker expression \[[@R16]\] compared to non-NED IBC cases. Of note, when the non-NED IBC were further classified into luminal and non-luminal cases, IBC-NED in fact showed an intermediate outcome, which was better than non-luminal but worse than non-NED luminal cancers. Possibly the heterogeneity in the cohort and variation in diagnostic criteria contributed to the variation in its prognostication.

As IBC-NED is heterogeneous, factors that further stratify IBC-NED into different prognostic groups could be useful for the management of these cancers. DCLK1 expression was found to be an independent favorable prognostic factor for DFS in IBC-NED regardless of the NED expression pattern. Currently, there are no specific recommendations for treatment of IBC-NED and these cases are treated as IBC-NOS. As IBC-NED are mostly luminal, they are treated with either endocrine therapy alone or together with adjuvant chemotherapy, with the latter depending on risk assessment. The additional independent prognostic impact of DCLK1 could be crucial for therapeutic decision to identify IBC-NED with favorable outcome, and sparing patients from chemotherapy. The mechanism of its good prognostic impact of DCLK1 in IBC-NED has not yet been explored. A recent report suggested that DCLK1 can antagonize Runx2 \[[@R30]\]. Runx2 has been shown to be a regulator of epithelial cell fate in mammary gland development and breast cancer \[[@R31]\]. Overexpression of Runx2 drove EMT--like changes in normal mammary epithelial cells, whereas its deletion in basal breast cancer cells inhibited cellular phenotypes associated with tumorigenesis \[[@R32]\]. In fact, in our preliminary study on Runx2 expression, we observed a significantly higher expression of basal marker in DCLK1loRunx2hi cases compared to the others (data not shown). Interestingly, there are also interactions between them in IBC-NED patients\' outcome. Cases with DCLK1loRunx2hi expression were found to have significantly worse DFS than other subgroups (data not shown). Our data may suggest that DCLK1 could at least partly act via Runx2.

In summary, DCLK1 was found to be a good prognostic factor in breast cancer, particularly in IBC-NED. The result was in contrast to its tumor promoting roles in gastrointestinal cancers, suggesting different functional roles of DCLK1 in different type of cancers. In addition, using the current WHO classification, we found that IBC-NED showed a worse outcome, attributable in part to tumor heterogeneity. DCLK1 expression was shown to stratify IBC-NED into different prognostic groups. The findings could aid in the prognostication and management of this special type of IBC.

MATERIALS AND METHODS {#s4}
=====================

Patients data {#s4_1}
-------------

The histologic files of the three involved institutions were searched for IBC over periods of 2 (03-04), 4 (2002-05) and 7 (2003-09) years. All consecutive cases with excision specimens were included. All the specimens were formalin fixed, paraffin embedded and routinely processed. The 4 micron slides were stained with H&E and reviewed by two of the authors. The tumors were graded using modified Bloom and Richardson grading \[[@R16]\] and the histologic diagnosis was confirmed (WHO \[[@R17]\]). Invasive breast cancers with neuroendocrine differentiation (IBC-NED) were defined by the presence of neuroendocrine morphological features (neuroendocrine carcinoma) and the presence of neuroendocrine differentiation (NED) (neuroendocrine marker positivity) \[[@R17]\]. IBC was considered as having NED if ≥ 1% tumor cells showed any expression of GC and/or SYN or showing morphologic features of NED \[[@R18], [@R19]\]. In addition, lymphovascular invasion (LVI), the presence of extensive in situ components (EIC) and fibrotic focus (FF) were also evaluated as present or absent as previously reported \[[@R20]\]. Patient details and clinical information were retrieved from the medical records including patients\' age, tumor size, pN stage, pT stage and patient outcome data. For the outcome data, overall survival (OS) was defined as the time interval from the date of initial diagnosis to the date of breast cancer related death. Disease free survival (DFS) was defined as the duration from the date of initial diagnosis to the first detection of breast cancer specific relapse or death. The study was approved by Joint Chinese University of Hong Kong- New Territories East Cluster clinical research ethics committee.

Tissue microarray construction {#s4_2}
------------------------------

Cellular areas of the tumors on H&E slides were chosen and the corresponding areas were taken from the paraffin blocks for tissue microarray (TMA) construction. Two 0.6 mm tissue cores were obtained from each case. One additional core was taken from available nodal metastases. The TMAs were assembled with a tissue arrayer (Beecher Instruments, Silver Springs, MD). Sixty two composite TMA blocks, each containing maximum 54 tissue cores, were constructed. Serial 4 micron sections were cut and transferred to Superfrost Plus glass slides (Menzel-Glaser, Germany). One section from each tissue array block was stained with H&E to confirm the presence of representative tumors in the TMA blocks.

Immunohistochemistry and scoring {#s4_3}
--------------------------------

The TMA slides were assessed for the different groups of biomarkers, in addition to DCLK1. The first group were steroid hormone receptors (estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR)). The second group were growth factor receptors (human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR)) and a proliferation marker (Ki67). The other groups were neuroendocrine markers (chromogranin (CG) and synpatophysin (SYN)), basal markers (p63, c-kit, CK14 and CK5/6), cancer stem cell markers (CD44, SOX2 and ALDH1) and EMT markers (vimentin and p-cadherin). IHC of all markers was performed by BenchMark XT automated slide-staining instrument (Ventana, Arizona, USA) with Ultraview Universal DAB Detection Kit (Ventana, Arizona, USA) after deparaffinization, rehydration and antigen retrieval. After primary antibody incubation, the sections were incubated with anti-mouse horseradish peroxidase labeled polymer (Roche, Arizona, USA) for 30 min at room temperature, and then developed with diaminobenzidine. All slides were counterstained with hematoxylin. The TMA slides were scored for the intensity of staining in the nucleus, cytoplasm or membrane according to different antibodies by two of the authors blinded to the clinical information and the staining results of other markers. Details of the antibodies, antigen retrieval, staining conditions and scoring were listed in Table [1](#T1){ref-type="table"}. For DCLK1 staining, the reactivity assessed was cytoplasmic. DCLK1 was assessed for both intensity and proportion of positively stained cells. The staining intensity was graded from 0 to 3 whereas the proportion of stained cells was scored on a scale of 0-4 (0= no detectable staining, 1= 1-25% positive cells, 2= 26-50% positive cells, 3=51-75% positive cells and 4= over 75% positive cells). An immunoscore was obtained by adding the intensity score and the percentage score. Positivity for DCLK1 was defined using the mean immunoscore as the cutoff. Immunoscore of 0-3 was regarded as negative and \>3 as positive. Any discrepancies were resolved by reviewing at a multi-head microscope to reach a consensus.

The tumors were also classified into the 5 different molecular subtypes by immunohistochemical expression as surrogate as follows \[[@R21]\]: Luminal A: ER+ and/or PR+, HER2-, CK5/6 +/− and Ki67 \<14%Luminal B: ER+ and/or PR+, CK5/6+/−, HER2+ or Ki67 ≥14%HER2 over-expressed (HER2-OE): ER-, PR-, HER2+, CK5/6 +/−Basal like breast cancers (BLBC): ER-, PR-, HER2-, (triple negative), CK5/6+ and/or EGFR+Unclassified: ER-, PR-, HER2-, (triple negative), CK5/6- and EGFR-

Statistical analysis {#s4_4}
--------------------

The findings were analyzed using the statistical software SPSS for Windows, Version 18. Chi-square analysis or Fisher\'s exact test were used to test for the association of DCLK1 expression with tumor grade, FF, LVI, EIC, pN, pT, molecular subtypes and biomarker expression. Mann-Whitney U test was used for analyzing the differences in patient\'s age and tumor size with DCLK1 expression. The relationship of DCLK1 as a continuous variable with various clinico-pathologic features and biomarker expression was also analyzed with Mann-Whitney U test (for categorical data) and spearman correlation (rs) (for continuous variables). Survival data were evaluated with Kaplan Meier analysis and Cox regression analysis using the backward Wald method. Statistical significance was established at *p* \< 0.05.

SUPPLEMENTARY MATERIAL TABLES AND FIGURE {#s5}
========================================
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